Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma

European Journal of Endocrinology

Volumn 161, Issue 6, 2009, Pages 923-931

  Hoftijzer, Hendrieke ^a   Heemstra, Karen A ^a   Morreau, Hans ^a   Stokkel, Marcel P ^a   Corssmit, Eleonora P ^a   Gelderblom, Hans ^a   Weijers, Karin ^a   Pereira, Alberto M ^a   Huijberts, Maya ^b   Kapiteijn, Ellen ^a   Romijn, Johannes A ^a   Smit, Johannes W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; B RAF KINASE; IODINE 131; RECOMBINANT THYROTROPIN; SORAFENIB; THYROGLOBULIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LIVER METASTASIS; LUNG METASTASIS; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NUTRITIONAL SUPPORT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; TUMOR GROWTH; WEIGHT REDUCTION;

ADENOCARCINOMA, FOLLICULAR; AGED; AGED, 80 AND OVER; BENZENESULFONATES; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRIDINES; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 72949106263     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0702     Document Type: Article

References (45)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306.
2. Mazzaferri EL & Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2001 86 1447-1463.
3. Hundahl SA, Fleming ID, Fremgen AM & Menck HR. A National Cancer Data Base Report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998 83 2638-2648.
4. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, Martino E & Pinchera A. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal of Surgery 1994 18 600-604.
5. Schlumberger M, Challeton C, De Vathaire F & Parmentier C. Treatment of distant metastases of differentiated thyroid carcinoma. Journal of Endocrinological Investigation 1995 18 170-172.
6. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M & Parmentier C. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. Journal of Nuclear Medicine 1996 37 598-605.
7. Arturi F, Russo D, Schlumberger M, du VJ, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG & Filetti S. Iodide symporter gene expression in human thyroid tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 2493-2496.
8. - symporter distribution in human thyroid tissues: an immunohistochemical study. Journal of Clinical Endocrinology and Metabolism 1998 83 4102-4106.
9. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism 1999 84 3228-3234.
10. Marcocci C, Pacini F, Elisei R, Schipani E, Ceccarelli C, Miccoli P, Arganini M & Pinchera A. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 1989 106 960-966.
11. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP & Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. Journal of Clinical Endocrinology and Metabolism 1988 67 501-508.
12. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & WiersingaW. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803.
13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI & Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 109-142.
14. Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E & Soares P. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Archiv 2005 447 787-793.
15. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal of Endocrinology 2004 183 249-256.
16. Soares P & Sobrinho-Simoes M. Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Pathology, Research and Practice 1995 191 304-317.
17. - targeting to the membrane. Endocrine-Related Cancer 2006 13 257-267.
18. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocrine Pathology 2002 13 271-288.
19. Cinti R, Yin L, Ilc K, Berger N, Basolo F, Cuccato S, Giannini R, Torre G, Miccoli P, Amati P, Romeo G & Corvi R. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenetics and Cell Genetics 2000 88 56-61.
20. Corvi R, Berger N, Balczon R & Romeo G. RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. Oncogene 2000 19 4236-4242.
21. Klugbauer S, Jauch A, Lengfelder E, Demidchik E & Rabes HM. A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Research 2000 60 7028-7032.
22. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H & Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 1997 57 1690-1694.
23. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della PG, Fusco A & Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990 60 557-563.
24. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G & Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994 9 509-516.
25. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G & Fusco A. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996 12 1821-1826.
26. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della PG & Berger N. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. Journal of Clinical Investigation 1992 89 1517-1522.
27. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M & Fusco A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995 11 1207-1210.
28. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C & Della PG. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992 7 237-242.
29. Xing M. BRAF mutation in thyroid cancer. Endocrine-Related Cancer 2005 12 245-262.
30. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003 22 4578-4580.
31. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A & Santeusanio F. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2004 89 2414-2420.
32. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K & Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003 22 6455-6457.
33. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR & Lynch TJ. A phase II study of Gefitinib in patients with advanced thyroid cancer. Thyroid 2008 18 317-323.
34. Cohen EEW, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF & Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 2008 26 4708-4713.
35. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ & Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719.
36. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ & The Motesanib Thyroid Cancer Study Group . Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 2008 359 31-42.
37. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PEJ, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M & Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684.
38. De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Lauro R, Fusco A & Santoro M. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth & Differentiation 1998 9 97-103.
39. Fenton MS, Marion K, Salem AK, Hogen R, Naeim F & Hershman JM. Induction of cell cycle arrest by sunitinib through inhibition of the MEK/ERK pathway in RET/PTC1 papillary thyroid cancer cells. 90th Annual Meeting of the Endocrine Society, San Francisco (abstract), 1990.
40. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA & Smit JW. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology 2003 58 428-435.
41. V600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Journal of Clinical Endocrinology and Metabolism 2008 93 3943-3949.
42. Wapnir IL, van de RM, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohan O & Carrasco N. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue micro-arrays and conventional sections. Journal of Clinical Endocrinology and Metabolism 2003 88 1880-1888.
43. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N & Smit JW. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. European Journal of Endocrinology 2008 158 375-384.
44. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T & Kobayashi T. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004 145 2865-2875.
45. Salem AK, Fenton MS, Marion KM & Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008 18 631-635.